Related Experiment Video
Updated: Apr 19, 2026
08:15
Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
Published on: August 15, 2025
1.3K
Metformin: the past, presence, and future
1Institute for Postgraduate Medical Education, Prague, Czech Republic - Paluch.Z@seznam.cz.
Minerva Medica
|December 24, 2014
Summary
Metformin, a diabetes drug, shows potential for treating other conditions due to newly discovered properties. Ongoing trials will determine if its use expands beyond blood sugar control.
Area of Science:
- Pharmacology
- Endocrinology
- Internal Medicine
Background:
- Metformin is a widely used medication primarily for type 2 diabetes.
- Its established efficacy in glycemic control is well-documented.
Purpose of the Study:
- To review the historical use of metformin.
- To explore emerging evidence on metformin's novel properties and potential applications beyond diabetes treatment.
Main Methods:
- Literature review of historical data.
- Analysis of recent experimental and clinical findings on metformin's mechanisms and effects.
Main Results:
- Metformin's history and current clinical applications are detailed.
- New insights reveal metformin's potential utility in non-diabetic conditions.
Conclusions:
- Metformin exhibits properties suggesting broader therapeutic applications.
- Further clinical trials are necessary to validate these novel uses and confirm metformin's expanded role in medicine.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
999
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
999
01:06Oral Hypoglycemic Agents: Glinides
1000
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1000
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:29Hyperglycemia
2
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
2
01:26Oral Drug Delivery Systems: Continuous-Release Systems
268
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
268
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
921
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
921